Rituxan hits targets in late-stage pemphigus vulgaris trial

14th October 2019 Uncategorised 0

The study is still ongoing, with patients participating in a 48-week safety follow-up period.

More: Rituxan hits targets in late-stage pemphigus vulgaris trial
Source: News